TrialInvestigational new drugs2013

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Pankaj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.